Applications of Benperidol in Industrial Manufacturing

Benperidol is a high-purity butyrophenone derivative produced under strict quality control for specialized use in regulated pharmaceutical manufacturing. As an established intermediate and active pharmaceutical ingredient (API), it serves in multiple highly controlled industrial processes.

1. Finished Dosage Form Production for Antipsychotic Medications

Pharmaceutical companies use Benperidol as an API in the production of oral and injectable antipsychotic medications. These finished forms require precise formulation, accurate dosing, and stringent documentation through validated batch records. The manufacturing process includes wet granulation, blending with excipients, tablet compression, and coating, or aseptic preparation for ampoules and vials. Strict traceability is maintained from incoming API through to finished packaging.

Industry compliance standards

• Compliance with current Good Manufacturing Practice (cGMP) as per US FDA 21 CFR Parts 210/211
• EU GMP guidelines (EudraLex Vol. 4)
• Ph. Eur. and USP monographs for APIs and oral dosage forms
• Relevant International Conference on Harmonisation (ICH) guidelines (Q7, Q8, Q10)

Typical usage ratio

• API concentration in finished products typically ranges from 0.5 mg to 10 mg per oral unit, adjusted according to indication and regulatory market. Tablets often contain 2 mg of active substance per unit, with exact ratios defined in registered dossiers.

Downstream process integration

• API is dispensed and weighed under class 100 cleanroom conditions, then incorporated into blender with excipients, followed by direct compression or wet granulation and final packaging under validated HVAC and environmental controls.

Final product types

• Antipsychotic tablets (various strengths)
• Film-coated tablets
• Sterile injectable solutions
• Oral suspensions (where authorized)

2. Bulk API Manufacturing and Export

Drug substance manufacturers use Benperidol as a main product or as an upstream intermediate in multistep synthesis. Production involves chemical synthesis, crystallization, purification, and micronization, with process validation and in-line analytical controls. Batch records and analytical data accompany each lot, ensuring seamless handover to downstream drug product manufacturers globally.

Industry compliance standards

• International API GMP (ICH Q7)
• Certificate of Suitability (CEP) to Ph. Eur. monograph where needed
• WHO Prequalification where applicable
• ISO 9001:2015 quality management systems

Typical usage ratio

• Crude synthesis batches yield from kilogram up to multi-ton scale, with process adjustments based on impurity profiles, solvent recovery, and crystallization efficiency. Final API potency must consistently meet specification: ≥98% as per monograph.

Downstream process integration

• Intermediate is introduced during later synthetic stages, purified by recrystallization and dried, then milled and micronized. Final API is analyzed by HPLC and supplied in tamper-evident fiber drums with full CoA and data package for registration dossiers.

Final product types

• Bulk pharmaceutical API for licensed drug manufacturers
• Technical grade for further chemical modification (as per local laws)
• Micronized API for high-solubility applications

3. Reference Standard Supply for Analytical Laboratories

Quality control laboratories and pharmaceutical analytical service providers use high-purity Benperidol as a reference standard for method development, pharmacopoeial assay validation, and stability testing of antipsychotic finished products. Material must meet strict certification requirements regarding impurity profiling, homogeneity, and documentation of origin, supporting both internal QC programs and regulatory batch release.

Industry compliance standards

• Ph. Eur. and USP monographs for reference materials
• ISO/IEC 17025 (general requirements for the competence of testing and calibration laboratories)
• Documented traceability to certified reference material (CRM) standards
• OECD Principles of Good Laboratory Practice (GLP)

Typical usage ratio

• Laboratories typically use 10–50 mg per batch analysis, depending on method sensitivity, stability requirements, and number of test replicates. Dilution levels are set according to HPLC/GC/FID or spectrometric detection protocols.

Downstream process integration

• Benperidol reference material is weighed, dissolved in analyte-compatible solvents, and used for calibration curves, specificity testing, and impurity identification. Full traceability from primary lot is maintained in laboratory documentation.

Final product types

• Certified reference standards for laboratory use
• Analytical control samples for QC and QA
• Method validation kits supplied to pharmaceutical plants

4. Active Ingredient in Clinical Research Formulation

Clinical trial material manufacturers and contract research organizations (CROs) require Benperidol as an active ingredient for the formulation of investigational medicinal products (IMPs) used in Phase I to III studies. The material must come with comprehensive data on identity, purity, and stability, enabling reliable assessment of pharmacokinetics, safety, and bioequivalence studies in volunteer and patient settings.

Industry compliance standards

• ICH GCP (Good Clinical Practice) E6(R2) Guideline
• EU GMP Annex 13 for IMPs
• FDA IND requirements for clinical supply
• OECD GLP for preclinical batches

Typical usage ratio

• Dosing formulations typically contain 0.5–10 mg per unit, with protocol-defined adjustment based on subject tolerance, clinical phase, and regional regulatory requirements. Batch sizes range from hundreds to a few thousand units per clinical lot.

Downstream process integration

• Active is integrated into pilot-scale blending and tableting or filling lines under blinding conditions, with full batch reconciliation and material accountability for investigational supply chains.

Final product types

• Blinded capsules or tablets for clinical research
• Matching placebos for comparator studies
• IMP kits assembled for multicenter trials